As a national class I innovative drug, Sanbexin^® can improve the neurological function of patients with strokes by inhibiting the dual mechanisms of oxidative stress damage and inflammatory damage. Sanbexin^® owns eight patents, with core patents authorized in the US, Japan and European countries and regions. It has received national special support for "Significant New Drug Development" and been awarded as one of “China’s Milestone Medical Achievements During the 13th Five-Year Plan Period”.